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Management of Mycoplasma genitalium
infections – can we hit a moving target?
Jørgen Skov Jensen1* and Catriona Bradshaw2,3
Abstract
Mycoplasma genitalium is an etiological agent of sexually transmitted infections, but due to its fastidious growth
requirements, only a few M. genitalium strains are available for determination of the activity of currently used and
new antimicrobial agents.
Recent clinical trials have demonstrated that treatment with azithromycin has decreasing efficacy due to an
increasing prevalence of macrolide resistance, which is likely to be attributed to the widespread use of 1 g single
dose azithromycin. Second line treatment with moxifloxacin is similarly under pressure from emerging resistance.
The era of single dose monotherapy for uncomplicated STIs such as M. genitalium and N. gonorrhoeae, while
convenient for patients and physicians, has been associated with escalating resistance and treatment failure and is
now drawing to a close. There is a critical need for trials of combinations of existing registered drugs and new
antimicrobial compounds, implementation of diagnostic testing combined with molecular detection of resistance,
and antimicrobial surveillance.
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Review
The importance of M. genitalium in genital syndromes
Mycoplasma genitalium was first isolated in 1980 from
two of 13 men with non-gonococcal urethritis (NGU)
[1]. It is an extremely slow-growing and fastidious bacter-
ium, and progress in determining its role as a pathogen in
human disease was hampered by the lack of reliable detec-
tion methods. After the development of the first diagnostic
PCRs in the early 1990’s [2, 3], studies on male NGU
started to accumulate [4, 5]. M. genitalium is now a well-
established sexually transmitted infection and the etio-
logical agent of a number of syndromes (reviewed in [6, 7]).
Several studies have demonstrated the association between
M. genitalium and urethritis, cervicitis, endometritis, and
pelvic inflammatory disease (PID) [8–11]. In a recent meta-
analysis [12], significant associations were found between
M. genitalium and cervicitis (pooled odds ratio (OR) 1.66),
and pelvic inflammatory disease (pooled OR 2.14). While
there are less data in pregnancy, M. genitalium has been
associated with preterm birth (pooled OR 1.89), and
spontaneous abortion (pooled OR 1.82) [12], but the preva-
lence of M. genitalium in pregnant women has been low in
some settings [13]. Serological studies and studies based on
detection of M. genitalium using NAATs have also shown
an association with increased risk of tubal factor infertility
(pooled OR 2.43) [12]. In sub-analyses that accounted for
co-infections, Lis et al. found these associations to be
stronger and more statistically significant [12].
Several studies have demonstrated the association be-
tween M. genitalium and urethritis in men [4, 14–17] and
in a meta-analysis including 37 studies up to 2010 [6], M.
genitalium was associated with a pooled OR of 5.5 for
NGU. In the 29 studies where information on chlamydial
infection was available, M. genitalium was associated with
a pooled OR of 7.6 for non-chlamydial non-gonococcal
urethritis (NCNGU) [6]. The prevalence of M. genitalium
in men with NCNGU ranges from 10 % to 35 % [6], thus
contributing significantly to the overall burden of disease.
In comparison, M. genitalium is detected in only 1 % to
3.3 % of men and women in the general Western European
and United States population [18–20].
Signs and/or symptoms of urethritis persist in patients
in which antibiotic treatment fail. In men with persistent
NCNGU after doxycycline therapy, as many as 41 %
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were found to be M. genitalium positive [21], and 91 %
of patients with persistent M. genitalium infection expe-
rienced persistent urethral symptoms compared to 17 %
of patients in whom M. genitalium was eradicated [22].
A total of 21 studies have examined the efficacy of treat-
ment of M. genitalium positive urethritis, and presented
data on the presence of urethritis in patients where anti-
biotic treatment failed to eradicate the infection [22–42].
Of the 310 patients with persistent M. genitalium infec-
tion, 240 (77 %) had persistent urethritis (defined as
persistent urethral symptoms and/or signs). In the 19
studies where data on both men with persistent and eradi-
cated M. genitalium infection could be evaluated, of the
285 patients with persistent M. genitalium infection, 220
(77 %) had persistent urethritis, compared to only 78
(16 %) of the 499 patients where M. genitalium was suc-
cessfully eradicated (p < 0.0001). Analysing the 19 studies
using random effects (DerSimonian-Laird method), per-
sistent M. genitalium was associated with a pooled odds
ratio of 26 (95 % CI = 11 to 57) for persistent urethritis
(signs and/or symptoms). A forest plot illustrating the
odds-ratios for the individual studies is shown in Fig. 1.
Two studies reported no treatment failures, and ORs
could therefore not be calculated [29, 33]. This analysis
clearly shows that failure to eradicate M. genitalium
leads to persistent or recurrent signs and symptoms of
urethritis in a significant proportion of men with per-
sistent infection.
Fig. 1 Meta-analysis of the risk of persistence of urethritis signs and/or symptoms in patients with and without eradication of Mycoplasma
genitalium. Data from 19 studies included; in two studies, OR could not be calculated due to eradication of M. genitalium in all patients
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Antimicrobial treatment of M. genitalium
Similar to other mycoplasmas, M. genitalium lacks a rigid
peptidoglycan containing cell wall [43] and, consequently,
β-lactam antibiotics and other antibiotics targeting the cell
wall are not active. Determining the spectrum of anti-
microbial susceptibility in vitro has been hampered by
the limited number of strains capable of growing well
enough in mycoplasma broth or agar to enable determin-
ation of the minimal inhibitory concentration (MIC) by
standard Clinical and Laboratory Standards (CLSI) ap-
proved methods [44]. However, it has been shown that
using susceptibility testing based on antimicrobial growth
inhibition of M. genitalium in Vero cell culture, provides
similar results to those obtained by conventional methods
[45, 46], and, consequently, larger collections including
fastidious strains could be tested [47].
Early in vitro studies with few strains showed that
M. genitalium was highly susceptible to tetracyclines and
macrolides, particularly to azithromycin, but that it had
reduced susceptibility to older quinolones such as ofloxa-
cin and ciprofloxacin [48]. When more strains were stud-
ied, it became clear that some strains were resistant to the
older quinolones with MIC90 (the MIC covering 90 % of
the tested strains) for ciprofloxacin at 8 mg/l. However, all
of these strains were susceptible to moxifloxacin and other
quinolones with extended Gram-positive spectrum such as
sitafloxacin, sparfloxacin, and gatifloxacin [46, 49]. With the
emergence of resistance to both macrolides and quinolones
as described below, the need for contemporary and repre-
sentative strain collections has become evident in the
search of new treatment modalities.
Clinical efficacy of commonly used antimicrobials
Doxycycline
In vitro susceptibility testing suggests that most M. genita-
lium strains would be susceptible to doxycycline with a
MIC50 of 0.25 mg/l and a MIC90 of 1 mg/l among 39
strains examined [47]. This is in striking contrast to clinical
experience that predominantly showed poor efficacy of
doxycycline in eradication of M. genitalium [50]. A single
exception is an early study where 33 (94 %) of 35 men were
M. genitalium negative after doxycycline treatment [51]. It
should be noted, however, that eradication was evaluated
only one week after treatment, and may reflect temporary
suppression of the M. genitalium load, which has been
reported in a study by Mena et al. [31] where 47 % of men
with early clinical cure after doxycycline experienced a sub-
sequent relapse. In controlled clinical trials, the microbio-
logical cure rate has ranged between 22 % and 45 % [30, 31,
52, 53]. The reason for the discrepancy between in vitro
and in vivo activity is not clear, but at least two studies
[30, 38] have found that eradication rates in women were
slightly higher than in men (37 % vs 17 %, and 48 % vs
38 %, respectively). Whether this is a reflection of lower
compliance in men in relation to the nine-day doxycycline
regimen used in these studies, or of an inaccessible pros-
tatic focus of M. genitalium, remains speculative. However,
based on these data doxycycline cannot be recommended
for first line treatment ofM. genitalium infection.
Azithromycin
In published studies, the majority of M. genitalium
infected patients have been treated with azithromycin, and
in early susceptibility studies [48], this macrolide was
shown to be very potent. In patients with STIs, treatment
with a 1 g single dose of azithromycin was well docu-
mented to be active in eradication of C. trachomatis [54],
and the idea of a single-dose treatment was appealing for
STI patients and widely adopted in many nations as first
line treatment for NGU and M. genitalium. However, in
M. pneumoniae pneumonia an extended treatment of
500 mg day one followed by 250 mg once daily on days
two to five (referred to subsequently as extended azithro-
mycin) was shown to be as effective as erythromycin for
ten days [55]. Based on early, unpublished observations
regarding the poor efficacy of doxycycline, Scandinavian
researchers agreed that a slow-growing bacterium such as
M. genitalium would need treatment for an extended
period. Following the reported effect of extended azithro-
mycin on the closely related M. pneumoniae [55], and
approval of this regimen for treatment of pneumonia from
the regulatory bodies, it was decided that this 5 day
extended azithromycin regimen should be the preferred
treatment for M. genitalium infections in Denmark,
Norway and Sweden. A number of other extended regi-
mens were considered, including giving a 1 g dose on day
one in order to comply with treatment guidelines for
C. trachomatis, and then supplementing with 250 mg on
days two to five. This regimen may have increased the
acceptance of the idea of extended treatment among phy-
sicians treating STIs, and would not be expected to have
adverse influence on the treatment of M. genitalium.
However, eradication of C. trachomatis infections with the
5 day extended azithromycin regimen has recently been
documented [56].
Over the years, controversy has existed over the optimal
dosage of azithromycin [57]. Importantly, no randomised
controlled trial has compared azithromycin 1 g single dose
with extended azithromycin, but a few observational stud-
ies and one treatment trial [30, 38, 58, 59] have included
patients treated with both regimens. In the four studies,
469M. genitalium infected patients received azithromycin
as a 1 g single dose, and 244 received extended azithromy-
cin with microbiological cure rates of 81 and 88 %,
respectively (p = 0.026). It should be noted, however, that
a large proportion of the patients receiving the extended
azithromycin had it as a second line treatment, most often
after doxycycline, impacting on direct comparison of the
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two azithromycin regimens. One of the emerging concerns
with M. genitalium is that the 1 g single dose may be more
likely to select for macrolide resistance compared to the
extended regimen [57]. No data from controlled trials are
available, and only a single observational study [38] has
examined the development of resistance after extended azi-
thromycin. This study found that none of 25 patients (0 %
[95 % CI 0-13 %]) treated with extended azithromycin first
line developed resistance, and, similarly, none (0 % [95 %
CI 0-7 %]) of 52 patients who received extended azithromy-
cin second line after doxycycline developed macrolide
resistance. This contrasts with the risk of development of
post-treatment resistance reported among 318 patients
treated with a 1 g azithromycin in six studies, which was
10 % (95 % CI 7-14 %) [27, 38, 41, 60–62]. The 7 % differ-
ence in microbiological cure rate between 1 g single dose
and extended azithromycin regimens calculated above is
strikingly similar to the 10 % risk of development of post-
treatment resistance after 1 g single dose azithromycin,
lending support to the concept that single dose therapy ap-
pears to be associated with selection of resistance compared
to extended regimens. The likely consequence of such rapid
selection of resistant mutants without an efficient method
to remove them from the population, is escalating macro-
lide resistance in high-risk populations. This situation
appears to be playing out in countries where the use of 1 g
azithromycin is widespread for chlamydia and its associated
syndromes, and testing for M. genitalium is often restricted
to speciality services or unavailable. Data from some of
these nations, including in Greenland [63], Australia [60],
Japan [64] and the UK [65], indicate macrolide resistance
mutations are now detected in 30-100 % of cases with
M. genitalium.
Macrolide resistance in M. genitalium is primarily
caused by mutations in nucleotide 2058 or 2059 (Escheri-
chia coli numbering) in region V of the 23S rRNA gene
[66] although mutations in position 2062 have been
described after treatment with josamycin in vivo [42] and
in M. pneumoniae by in vitro selection [67]. Analogous to
M. pneumoniae, it would be expected however, that
strains with mutations in position 2062 would retain
susceptibility to azithromycin. M. genitalium has only one
ribosomal RNA operon, and as mycoplasmas have a high
mutation rate [68], single nucleotide changes that confer
high-level antimicrobial resistance would also be likely to
be randomly present in a population of M. genitalium
cells (heterotypic resistance). This could explain the recent
observed association in three studies between a high
organism load and increased risk of treatment failure
following both azithromycin and josamycin [41, 42, 62].
Bissessor et al. reported in men with urethral M. genitalium
that for each log10 increase in organism load there was
a significant increase in the odds of 1 g azithromycin
failure (adjusted OR, 1.8, p = .018) [41]. Macrolides are
bacteriostatic, and it is therefore possible that a high
initial organism load could lead to a larger number of
organisms surviving the initial peak concentrations of
azithromycin, with replication of the surviving cells en-
suing when concentrations drop below the MIC leading
to a situation where spontaneously occurring mutations
would be readily selected. Overall, the body of evidence
suggests that both heterotypic resistance with a minor-
ity population of resistant strains being present before
initiation of treatment and resistance developing during
treatment are likely to play a role in macrolide failure,
with peak concentration and duration of antibiotic
exposure, together with organism load, contributing to
the survival and emergence of resistant mutants.
Cure rates for M. genitalium following 1 g azithromycin
appear to be declining internationally, with evidence of a
lower cure rate in studies where patients were recruited
most recently. In Fig. 2, 19 studies were stratified according
to the mid-date of the reported patient inclusion. In the
seven studies recruiting patients in the first half of the ob-
servation period before December 2005 [10, 28–31, 51, 69],
222 (87 %) of 255 patients were microbiologically cured. In
contrast, for the 12 studies with mid-enrolment after
November 2005 [22, 32, 39, 41, 52, 53, 58–62, 70], only 660
Fig. 2 Microbiological cure rate of M. genitalium infections after
azithromycin 1g single dose (blue diamonds) in 19 studies stratified
according to the mid-date of the reported patient inclusion. In seven
studies, data for cure rates after doxycycline treatment were available
(red squares)
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(71 %) of 925 patients were cured (p < 0.0001). Seven of the
studies also presented data on doxycycline treatment, and
apart from the early study by Gambini et al. [51], cure rates
were low, between 22 and 45 % (Fig. 2) but without an
evident time trend.
Quinolones
Quinolones have been used in the treatment of M.
genitalium, but based on in vitro susceptibility studies, it
was predicted that second generation fluoroquinolones
(ciprofloxacin and ofloxacin) would be inefficient in
eradicating M. genitalium and this was confirmed in
observational studies [23, 58] with an overall cure rate of
59 %. From in vitro data [46], the third generation quin-
olone levofloxacin appeared more promising, but in
observational studies, again it only achieved a cure rate
of 54 % in 82 treated patients [24, 34, 70, 71]
Moxifloxacin is a fourth generation quinolone and it
has been one of the most commonly used second line
antimicrobials being reported first in 2006 [27], although
it had been used several years before. Moxifloxacin is
bactericidal, and generally well tolerated, and in early
studies, it appeared to have a cure rate approaching 100 %
[22, 27, 38, 58]. However, warnings of possible hepatotox-
icity were added to the US labelling in 2007, and in 2008,
moxifloxacin was restricted to second line indications in
Europe [72]. However, these serious adverse events were
subsequently shown to be no more common in patients
treated with moxifloxacin as monotherapy, than in pa-
tients treated with amoxicillin or with doxycycline [72].
Aside from concerns of adverse events, a declining cure
rate for moxifloxacin has now been observed, primarily in
patients from the Asia-Pacific region. Treatment failures
have recently been reported in up to 30 % of patients
treated with moxifloxacin, and a significant proportion of
these patients’ strains had concurrent macrolide resistance
mediating mutation leaving very few available treatment
options [41, 59, 61, 70]. Resistance to moxifloxacin and
other fourth generation quinolones is mediated by muta-
tions in quinolone resistance determining regions (QRDR)
of the parC gene, primarily in the hotspots in amino acid
positions S83 and D87 (M. genitalium numbering) [73, 74]
reported also in M. pneumoniae, M. hominis and U.
urealyticum [75–77]. Based on data on in vitro selection of
resistance in M. pneumoniae, supporting mutations in
gyrB or parE may also be needed to reach resistant MIC
levels [77], but this has not yet been definitely determined
for M. genitalium. Mutations in the relevant positions have
been found at a low rate in Europe with only 1 (5 %) of 22
samples from London, UK [65] and even lower than
this in Denmark (Jensen, unpublished). In the Asia-
Pacific region, however, evidence of fluoroquinolone mu-
tations and associated treatment failure is emerging. In an
Australian STI clinic 15 % of 143 specimens collected
between 2008 and 2011, carried mutations that were asso-
ciated with fluoroquinolone resistance [78]. Similarly, a
report from Japan [64] found parC mutations in 17 (33 %)
of 51 specimens collected between 2011 and 2013, with a
dramatic increase from 20 % in 2011 to 47 % in 2013. It is
important to note, however, that the in vitro and in vivo
correlates of mutations in the QRDR for several of the
reported mutations have not yet been established. The
increasing trend of parC mutations reported from Japan
was mainly due to an S83N mutation [64], and this substi-
tution between two polar amino acids with uncharged
side-chains has been shown not to change the moxifloxa-
cin MIC from that of the susceptible wild-type G37 M.
genitalium type-strain (Jensen, unpublished). This obser-
vation probably explains the remarkable 100 % cure-rate
of sitafloxacin in nine M. genitalium infected patients with
mutations in the QRDR of parC, eight of whom carried
the indifferent S83N mutation.
Other fourth generation quinolones have been used in
Japan. Gatifloxacin (now withdrawn from the market)
cured 90 % of 48 patients [33, 71] and sitafloxacin has been
used in five studies [36, 37, 39, 64, 70] with cure rates ran-
ging from 100 % to 85 % with an overall cure rate of 95 %
in 105 patients. In vitro, sitafloxacin also appear to have a
good activity with MICs for moxifloxacin susceptible strains
approximately one dilution step below that of moxifloxacin
[46]. For moxifloxacin resistant strains, the MIC is cur-
rently being examined, but for one moxifloxacin resistant
strain, an encouraging MIC of 1 mg/l has been found
(R. Hamasuna, personal communication).
Other licensed but less commonly used antibiotics
Pristinamycin Pristinamycin is an oral streptogramin
antibiotic with bactericidal activity against Gram-positive
organisms including methicillin-resistant Staphylococcus
aureus (MRSA). It has a high activity against macrolide
susceptible M. genitalium strains [48] and even for strains
with combined macrolide and moxifloxacin resistance, the
MIC remained <1 mg/l (Jensen, unpublished). Pristinamy-
cin has been used for decades, particularly in France, for
treatment of MRSA, but is not registered outside of
France and some North-African countries. In M. pneumo-
niae, it has a relatively lower risk of development of resist-
ance than azithromycin in vitro, and the selected mutants
retained an azithromycin susceptible phenotype [67]. How
a strain with pre-existing azithromycin resistance would
react to selection with pristinamycin remains unknown, but
in vitro selection studies are currently ongoing. Pristinamy-
cin has been successfully used as third line treatment for
patients infected with multidrug resistant M. genitalium
strains. As most of these patients were facing their last
known active antimicrobial therapy, the maximal recom-
mended dose of 1 g four times orally a day for 10 days was
used. Several patients in Scandinavia have responded well
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to this treatment, and recently a case series from Australia
demonstrated six cases with successful eradication [41].
Using pristinamycin as a second line antibiotic instead of
moxifloxacin would probably be hampered both by the
price of pristinamycin and of the compliance issues associ-
ated with four times a day dosage. Whether lower daily
doses would be effective remains to be determined, but
for patients failing azithromycin, moxifloxacin, and possibly
14 days of doxycycline, a dose reduction is not advisable
due to the proportion of these multidrug resistant
strains that have an elevated MIC of 0.5 mg/l (Jensen,
unpublished).
Antimicrobials under development
Solithromycin is a newly developed fluoroketolide (CEM-
101), a further development of the macrolides. It has a
potent activity against azithromycin susceptible M. genita-
lium strains and to some extent also against azithromycin
resistant strains [47]. Susceptibility to solithromycin ap-
pears to differ according to the type of macrolide resis-
tance mediating mutation present, with eight strains
harbouring mutations in position A2059 having suscep-
tible MICs <2 mg/l, but only two of five strains with the
A2058G mutation with susceptible MICs [47]. Using a
clinical scenario seen in Denmark where 60 % of azithro-
mycin resistant strains carry the A2058G mutation [79],
one would expect to achieve a 65 % cure rate with the use
of solithromycin for azithromycin resistant strains [47].
Treatment trials of single dose solithromycin for patients
with gonorrhoea are currently underway, and in one study,
a few cases of concomitant M. genitalium infections have
been detected of which some have been eradicated [80];
however, data on the efficacy of solithromycin for M.
genitalium is limited. Treatment trials targeting patients
with NGU are likely to need a longer treatment duration in
order to coverM. genitalium infections.
Lefamulin (BC-3781) belongs to the pleuromutilin class
of antimicrobials, which has been used for decades in the
veterinary industry for infections in pigs, and to a lesser ex-
tent in poultry, but this class has not previously been devel-
oped for human use. Lefamulin has a very potent activity in
vitro with MIC ≤ 0.06 mg/l against multidrug resistant
M. genitalium strains [81]. In the veterinary mycoplasmas,
mutations in position A2058 have been associated with
increased MIC levels, but only in a background of other
mutations in the 23S rRNA gene, suggesting multistep
development of significant resistance [82]. Lefamulin has
successfully completed phase II trials for skin and soft
tissue infections [83] and is currently entering trials for
community-acquired pneumonia. It has not been studied
in the treatment of STIs or specifically M. genitalium.
A novel spiropyrimidinetrione AZD0914 (a DNA gyr-
ase inhibitor) has been tested against azithromycin and
quinolone susceptible strains of M. genitalium and MIC
<1 mg/l was reported for 11 strains [84]. No reports on
human use of this interesting class of compounds have
been published.
LBM415 belongs to a new antimicrobial class, the pep-
tide deformylase inhibitors which inhibit bacterial pro-
tein synthesis. The compound has high in vitro activity
against M. pneumoniae and was efficient in eradicating
the bacterium in a mouse model [85], but unfortunately,
prolonged high dosage produced methaemoglobulinae-
mia [86] and further development of the compound has
apparently been stopped.
Possible use of other registered antimicrobials
Although tetracyclines appear to be active in vitro, they
have never shown evidence of sufficient efficacy clinically.
Whether newer modifications of the tetracyclines such as
the glycylcycline tigecycline would be active in M. genita-
lium infections remain to be determined. This antibiotic is
active in vitro against M. pneumoniae [87], but at present,
no in vitro data are available for M. genitalium, and the
need for parenteral administration would not render it an
optimal treatment, except in otherwise untreatable infec-
tions. Linezolid with its Gram-positive spectrum does not
appear promising according to the MICs obtained for
M. pneumoniae [87], but it has not been evaluated for
M. genitalium.
Chloramphenicol has a relatively high MIC in vitro
(5-25 mg/ml) [49] and although organisms with an MIC
≤16 mg/l are considered susceptible, is not likely to be a
promising alternative. A derivative of chloramphenicol,
thiamphenicol, has been used in treatment of NGU [88]
and PID [89], and is reported to have a higher activity than
chloramphenicol against mycoplasmas. It is currently reg-
istered in Italy and Brazil. Spectinomycin is widely used in
the veterinary industry to treat mycoplasmal infections,
however, most often in combination with lincomycin,
probably to reduce the rapid development of resistance
and due to a synergistic effect. The spectinomycin MIC
breakpoint for N. gonorrhoeae is 32-64 mg/l and the MIC
for M. genitalium has been reported to be <25 mg/l [49].
Since spectinomycin is inactive against C. trachomatis but
has some activity against ureaplasmas, it has been used in
the past to substantiate the role of ureaplasmas in NGU
[90]. Spectinomycin may have a potential role as a treat-
ment option for multidrug resistant strains of M. genita-
lium but the need for parenteral administration would be
problematic. Lastly, successful eradication of ureaplasmas
has been reported in a hypogammaglobulinaemic patient
with untreatable urethritis after treatment with netilmicin
[91]. However, aminoglycosides would not be expected to
be active in vivo against M. genitalium, as even for the
most potent aminoglycoside, netilmicin, the MIC of some
M. genitalium strains was 25 mg/l [49]. Furthermore, as
M. genitalium is capable of surviving intracellularly
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[92, 93], aminoglycosides would not be optimal as
their intracellular concentration is very low.
Conclusions
M. genitalium has shown a remarkable capability to de-
velop antimicrobial resistance very rapidly after introduc-
tion of new treatment modalities. It has already become a
difficult bacterium to treat on a syndromic basis, and even
after specific detection, enormous local differences exist in
the prevalence of strains with macrolide resistance-
mediating mutations, highlighting the need for widespread
antimicrobial resistance surveillance. In the ideal clinical
setting, specific diagnostic tests for M. genitalium would
be as readily available as tests for C. trachomatis and N.
gonorrhoeae, and detection of M. genitalium would be ac-
companied or followed by molecular detection of macro-
lide resistance mediating mutations. For patients infected
with a macrolide susceptible strain, evidence suggests that
extended azithromycin should be the first-line treatment,
but a test of cure should be routinely performed at three
to four weeks, as resistance may develop even with the
extended regimen. Patients with macrolide resistance can
in most settings still be treated with moxifloxacin 400 mg
once daily for 7-10 days, but treatment failure can occur,
particularly in the Asia-Pacific region, where pre-existing
quinolone resistance is common and, therefore, a test of
cure 3-4 weeks after treatment is again highly recom-
mended. If a patient experiences failure of azithromycin
and moxifloxacin in the absence of reinfection, whether
doxycycline 100 mg twice daily for 14 days should be
attempted before pristinamycin is not clear, but the former
is more readily available in most clinical settings. Most
patients responding to doxycycline will have a negative
test of cure by the end of treatment [94], but if they are
still positive, treatment with pristinamycin 1 g four times
daily for 10 days is currently the only third or fourth line
antimicrobial treatment that is available. The important
question is what to do when this treatment fails, which
has been experienced by a limited number of patients but
will inevitably increase in the foreseeable future. Based on
the rapid emergence of resistance to first and second line
treatment options internationally, continuous monitoring
of the efficacy of treatment regimens for M. genitalium is
highly recommended in clinical settings. In patients failing
treatment, samples appropriate for culture should ideally be
collected in order both to isolate M. genitalium for con-
firmation of the in-vitro correlates of antimicrobial resist-
ance, and to elucidate the molecular mechanisms leading
to treatment failure.
In clinical settings where access to testing for M. genita-
lium is not currently available, consideration should be
given to changing presumptive treatment of NGU and
cervicitis from the current recommendation of 1 g
azithromycin to doxycycline in order to minimise the
development and escalation of macrolide resistance.
Patients failing doxycycline could then be subsequently
treated with extended azithromycin, or in settings where
macrolide resistance is already widespread, with moxiflox-
acin, if available. Access toM. genitalium testing in patients
failing secondary treatment is available in many coun-
tries or via international collaborations, and should be
used in these specific cases in order to optimise patient
management.
Future research should focus on in vitro evaluation
and subsequent treatment trials of untested, but regis-
tered antimicrobials, and emphasis should be on the
development of treatment algorithms including dual
therapy and resistance testing in order to minimise the
development of resistance. Such combination therapies
will need to be rapidly adopted and accompanied by
antimicrobial resistance surveillance in order to retain
susceptibility. As it has been the case for N. gonorrhoeae,
the rapid development of resistance in M. genitalium
highlights the fact that the era of single dose therapy for
uncomplicated STIs is long past. Combination therapy
and resistance testing together with the development
and evaluation of new classes of antimicrobials should
enable us to finally hit this fast moving target.
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